EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Incidence of hepatitis C virus infection in the prison setting: The SToP‐C study

Behzad Hajarizadeh iD, Joanne M Carson iD, Marianne Byrne, Jason Grebely iD, Evan Cunningham iD, Janaki Amin iD, Peter Vickerman iD, Natasha K Martin iD, Carla Treloar iD, Marianne Martinello iD, Andrew R Lloyd iD, Gregory J Dore iD und 1 weitere

Journal of Viral Hepatitis · 2024

DOI: 10.1111/jvh.13895 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2024. Verfasst von Behzad Hajarizadeh und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Kirby Institute, University of New Soth Wales (UNSW), Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Substance Abuse, Intravenous, Hepatitis C. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

People in prison are at high risk of HCV given high injecting drug use prevalence. This study evaluated HCV incidence and associated injecting drug use characteristics in prison. The SToP‐C study enrolled people incarcerated in four Australian prisons. Participants were tested for HCV at enrolment and then every 3–6 months (October‐2014 to November‐2019). Participants eligible for this analysis included those at‐risk of HCV primary infection (anti‐HCV negative) or re‐infection (anti‐HCV positive, HCV RNA negative) with follow‐up assessment. A total of 1643 eligible participants were included in analyses (82% male; median age 33 years; 30% injected drugs in prison; 1818 person‐years of follow‐up). Overall HCV incidence was 6.11/100 person‐years (95%CI: 5.07–7.35), with higher rate of re‐infection (9.34/100 person‐years; 95%CI: 7.15–12.19) than primary infection (4.60/100 person‐years; 95%CI: 3.56–5.96). In total population ( n = 1643), HCV risk was significantly higher among participants injecting drugs in prison [vs. no injecting; adjusted hazard ratio (aHR): 10.55, 95%CI: 5.88–18.92), and those who were released and re‐incarcerated during follow‐up (vs. remained incarcerated; aHR: 1.60, 95%CI: 1.03–2.49). Among participants who injected recently (during past month, n = 321), HCV risk was reduced among those receiving high‐dosage opioid agonist therapy (OAT), i.e. methadone ≥60 mg/day or buprenorphine ≥16 mg/day, (vs. no OAT, aHR: 0.11, 95%CI: 0.02–0.80) and increased among those sharing needles/syringes without consistent use of disinfectant to clean injecting equipment (vs. no sharing, HR: 4.60, 95%CI: 1.35–15.66). This study demonstrated high HCV transmission risk in prison, particularly among people injecting drugs. High‐dosage OAT was protective, but improved OAT coverage and needle/syringe programmes to reduce sharing injecting equipment are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Substance Abuse, IntravenousHepatitis CHumansMaleAdultFemaleHepacivirusPrisonsIncidenceReinfectionAustralia

Stichwörter der Autor:innen

HCVcohort studycorrectional facilitiesintravenous substance abuseopiate substitution treatment

Autor:innen und Institutionen

  • The Kirby Institute, University of New Soth Wales (UNSW), Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • Population Health Sciences, University of Bristol, Bristol, UK.
  • Division of Infectious Diseases & Global Public Health, University of California San Diego, San Diego, California, USA.
  • Centre for Social Research in Health, University of New Soth Wales (UNSW), Sydney, New South Wales, Australia.

ORCID-Profile: Behzad Hajarizadeh, Joanne M Carson, Jason Grebely, Evan Cunningham, Janaki Amin, Peter Vickerman, Natasha K Martin, Carla Treloar, Marianne Martinello, Andrew R Lloyd, Gregory J Dore

Förderung

  • Gilead Sciences
  • National Health and Medical Research Council

Zitieren

APA

Hajarizadeh, B., Carson, J. M., Byrne, M., Grebely, J., Cunningham, E., Amin, J., Vickerman, P., Martin, N. K., Treloar, C., Martinello, M., Lloyd, A. R., Dore, G. J., & SToP-C study group (2024). Incidence of hepatitis C virus infection in the prison setting: The SToP‐C study. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13895

Vancouver

Hajarizadeh B, Carson JM, Byrne M, Grebely J, Cunningham E, Amin J, et al. Incidence of hepatitis C virus infection in the prison setting: The SToP‐C study. Journal of Viral Hepatitis. 2024. doi:10.1111/jvh.13895

BibTeX
@article{Hajarizadeh2024,
  author = {Hajarizadeh, Behzad and Carson, Joanne M and Byrne, Marianne and Grebely, Jason and Cunningham, Evan and Amin, Janaki and Vickerman, Peter and Martin, Natasha K and Treloar, Carla and Martinello, Marianne and Lloyd, Andrew R and Dore, Gregory J and SToP-C study group, SToP-C study group},
  title = {Incidence of hepatitis C virus infection in the prison setting: The SToP‐C study},
  journal = {Journal of Viral Hepatitis},
  year = {2024},
  doi = {10.1111/jvh.13895}
}
Kostenlos starten →